Variantyx obtains $20M in funding
March 16, 2021 -- Hereditary disease testing provider Variantyx has obtained $20M in funding for its whole genome sequencing-based testing method. Read More
Vela Diagnostics adds 2 SARS-CoV-2 assays
February 26, 2021 -- Vela Diagnostics has added two SARS-CoV-2 assays to its portfolio: ViroKey SQ Flex SARS-CoV-2 genotyping and ViroKey SARS-CoV-2 ID reverse transcription polymerase chain reaction. Read More
Qiagen, Inovio to partner on cervical dysplasia test
February 24, 2021 -- Qiagen and Inovio have announced they will develop a next-generation sequencing test for HPV-linked advanced cervical dysplasia that can be used on Illumina's NextSeq 550Dx platform. Read More
Illumina partners with German university on genome sequencing
February 19, 2021 -- Illumina is joining forces with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tübingen in Germany on whole-genome sequencing. The two will evaluate WGS as a first-line diagnostic test for patients with genetic diseases and familial cancer syndromes. Read More
Variantyx debuts whole genome sequencing prenatal test
January 27, 2021 -- Hereditary disease testing provider Variantyx has entered the women's health market with the launch of its Genomic Unity Prenatal Analysis test at this week's Society for Maternal Fetal Medicine's 41st Annual Pregnancy Meeting. Read More
CDC awards Labcorp SARS-CoV-2 sequencing contract
January 8, 2021 -- The U.S. Centers for Disease Control and Prevention (CDC) has awarded Labcorp a contract to provide genomic sequencing of samples of the SARS-CoV-2 virus. Read More
Co-Diagnostics develops test for mutated COVID-19 strain in U.K.
December 22, 2020 -- Co-Diagnostics announced that it has developed a molecular test for mutations that have been associated with a new variant of the coronavirus that has been causing alarm. Read More
Bayer and Veracyte team up on thyroid cancer genomic profiling
December 22, 2020 -- Bayer and Veracyte are planning to work together on the genetic testing of patients with metastatic thyroid cancer. They will target patients whose disease is radioactive iodine refractory and who may be candidates for therapies targeted at particular mutations. Read More
Test identifies any infection from any sample in hours
November 11, 2020 -- A new rapid test can identify any infection from any type of bodily fluid in as few as six hours, possibly changing the way diseases are diagnosed and treated, according to a study published November 9 in Nature Medicine. Read More
Exact to acquire early cancer detection firm for $2B
October 28, 2020 -- Exact Sciences has agreed to acquire early cancer detection firm Thrive Earlier Detection in a deal worth up to $2.15 billion in cash and stock. The company also announced a second deal to acquire epigenetics firm Base Genomics. Read More